Rixubis (Hemophilia A and B)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis and Quality of Life 14
3.2 Symptoms 15
3.2.1 Hemophilia A and B 15
3.2.2 Inhibitors 16
4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Hemophilia A and B Diagnosis 18
4.1.2 Hemophilia A and B Treatment 18
4.1.3 Inhibitors Diagnosis 20
4.1.4 Inhibitors Treatment 20
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitive Assessment 23
6 Rixubis (BAX-326) 27
6.1 Overview 27
6.2 Efficacy 28
6.3 Safety 29
6.4 SWOT Analysis 29
6.5 Forecast 30
7 Appendix 31
7.1 Bibliography 31
7.2 Abbreviations 33
7.3 Methodology 35
7.4 Forecasting Methodology 35
7.4.1 Diagnosed Hemophilia Patients 36
7.4.2 Percent Drug-Treated Patients 36
7.4.3 General Pricing Assumptions 36
7.4.4 Individual Drug Assumptions 37
7.5 Physicians and Specialists Included in this Study 39
7.6 About the Authors 41
7.6.1 Authors 41
7.6.2 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43